title: Sequence determinants of subtype-specific actions of KCNQ channel openers.
abstract: Retigabine is a KCNQ voltage-gated potassium channel opener that was recently approved as an add-on therapeutic for patients with drug-resistant epilepsy. Retigabine exhibits very little specificity between most KCNQ channel subtypes, and there is interest in generating more potent and specific KCNQ channel openers. The present study describes the marked specificity of ICA069673 for KCNQ2 vs. KCNQ3, and exploits this property to investigate determinants of KCNQ subtype specificity. ICA069673 acts on a binding site in the voltage-sensing domain that is distinct from the putative retigabine site in the channel pore. ICA069673 has two separable effects on KCNQ channel activity. We identify two channel residues required for subtype specificity of KCNQ channel openers and show that these are sufficient to generate ICA069673 sensitivity in KCNQ3.
  
  
  
  Retigabine (RTG) is the first approved anti-epileptic drug that acts via activation of voltage-gated potassium channels, targeting KCNQ channels that underlie the neuronal M-current. RTG exhibits little specificity between KCNQ2-5 as a result of conservation of a Trp residue in the pore domain that binds to the drug. The RTG analogue ICA-069673 ('ICA73') exhibits much stronger effects on KCNQ2 channels, including a large hyperpolarizing shift of the voltage-dependence of activation, an ∼2-fold enhancement of peak current and pronounced subtype specificity for KCNQ2 over KCNQ3. Based on ICA73 sensitivity of chimeric constructs of the transmembrane segments of KCNQ2 and KCNQ3, this drug appears to interact with the KCNQ2 voltage sensor (S1-S4) rather than the pore region targeted by RTG. KCNQ2 point mutants in the voltage sensor were generated based on KCNQ2/KCNQ3 sequence differences, and screened for ICA73 sensitivity. These experiments reveal that KCNQ2 residues F168 and A181 in the S3 segment are essential determinants of ICA73 subtype specificity. Mutations at either position in KCNQ2 abolish the ICA73-mediated gating shift, but preserve RTG sensitivity. Interestingly, A181P mutant channels show little ICA73-mediated gating shift but retain current potentiation by the drug. Mutations (L198F and P211A), which introduce these critical KCNQ2 residues at corresponding positions in KCNQ3, transplant partial ICA73 sensitivity. These findings demonstrate that RTG and ICA73 act via distinct mechanisms, and also reveal specific residues that underlie subtype specificity of KCNQ channel openers.
authors: Department of Pharmacology, Alberta Diabetes Institute, University of Alberta, Edmonton, AB, Canada.
authors: Alice W
authors: AW
authors: Wang
authors: Department of Pharmacology, Alberta Diabetes Institute, University of Alberta, Edmonton, AB, Canada.
authors: Runying
authors: R
authors: Yang
authors: Department of Pharmacology, Alberta Diabetes Institute, University of Alberta, Edmonton, AB, Canada.
authors: Harley T
authors: 0000-0003-4357-4189
authors: HT
authors: Kurata
mesh_terms: D002219:Carbamates / Q000494:pharmacology*; D057809:HEK293 Cells; D006801:Humans; D015640:Ion Channel Gating; D051658:KCNQ2 Potassium Channel / Q000235:genetics / Q000502:physiology*; D051659:KCNQ3 Potassium Channel / Q000235:genetics / Q000502:physiology*; D049990:Membrane Transport Modulators / Q000494:pharmacology*; D008958:Models, Molecular; D009154:Mutation; D010655:Phenylenediamines / Q000494:pharmacology*
chemical_list: D002219:Carbamates; D051658:KCNQ2 Potassium Channel; C496914:KCNQ2 protein, human; D051659:KCNQ3 Potassium Channel; C496916:KCNQ3 protein, human; D049990:Membrane Transport Modulators; D010655:Phenylenediamines; C101866:ezogabine
keywords: KCNQ activator; KCNQ channel; M-current; epilepsy; potassium channel; retigabine